Related Experiment Video

Updated: Aug 19, 2026

Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice
10:13

Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice

Published on: August 12, 2014

The molecular genetics of therapeutic resistance in malignant astrocytomas

M T Jennings1, S Iyengar

  • 1Vanderbilt Ingram Cancer Center, Vanderbilt Medical School, Nashville, Tennessee, USA. mark.jennings@mcmail.vanderbilt.edu

American Journal of Pharmacogenomics : Genomics-Related Research in Drug Development and Clinical Practice
|August 15, 2002
PubMed

Insights

Malignant astrocytoma resistance to cancer therapies is poorly understood. New research suggests cell cycle genes, not just drug resistance proteins, significantly impact tumor progression and treatment insensitivity.

Area of Science:

  • Neuro-oncology
  • Cancer Biology
  • Molecular Genetics

Background:

  • Malignant astrocytomas (MA) have a poor prognosis, partly due to treatment resistance.
  • Mechanisms of MA resistance involve endothelial cells, the blood-brain barrier, and neoplastic cells.
  • While drug resistance proteins exist in MA, their direct contribution to prognosis is unclear.

Purpose of the Study:

  • To investigate the role of specific genes in malignant astrocytoma resistance to chemo- and radiotherapy.
  • To analyze the mechanisms of hypoxic-ischaemic selection for resistance in MA.
  • To explore the therapeutic repercussions of these resistance mechanisms.

Main Methods:

  • Analysis of malignant astrocytoma biopsy specimens.
  • Identification and study of drug resistance proteins (e.g., p-glycoprotein).
  • Investigation of cell cycle regulatory genes (Rb, p53, cyclins, kinases, inhibitors) and their products.
  • Examination of intratumoral environmental factors, including hypoxic-ischaemic conditions.

Main Results:

  • Classic drug resistance proteins are present in MA, but their prognostic significance is questionable.
  • Genes involved in cell cycle regulation (Rb, p53, cyclins) are increasingly relevant to MA progression and treatment insensitivity.
  • An interaction between cell cycle gene products and the tumor microenvironment drives a prognostically adverse selection process.

Conclusions:

  • Cell cycle regulation plays a critical role in malignant astrocytoma resistance, independent of traditional drug resistance mechanisms.
  • Hypoxic-ischaemic selection pressures may favor tumor cells with altered cell cycle regulation, leading to therapeutic resistance.
  • Understanding these novel resistance pathways is crucial for developing more effective MA treatments.

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing09:24

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing

Published on: June 9, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...